key: cord-1011246-vmhrt6bk
authors: Harjai, Kishore J.; Agarwal, Shikhar; Bauch, Terry; Bernardi, Mark; Casale, Alfred S.; Green, Sandy; Harostock, Michael; Ierovante, Nicholas; Mascarenhas, Vernon; Matsumura, Martin; Nawaz, Yassir; Scott, Thomas; Singh, Deepak; Stella, Joseph J.; Vijayaraman, Pugazhendi; Yost, Gregory; Blankenship, James C.
title: Coronary and structural heart disease interventions during COVID-19 pandemic: A road map for clinicians and health care delivery systems
date: 2020-06-10
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2020.06.013
sha: 9cd0ab88d6d9700c443f577a85d2f4b20294926b
doc_id: 1011246
cord_uid: vmhrt6bk

BACKGROUND: Because of the COVID-19 pandemic, cath labs have had to modify their workflow for elective and urgent patients. METHODS: We surveyed 16 physicians across 3 hospitals in our healthcare system to address COVID-19 related concerns in the management of interventional and structural heart disease patients, and to formulate system wide criteria for deferring cases till after the pandemic. RESULTS: Our survey yielded common concerns centered on the need to protect patients, cath lab staff and physicians from unnecessary exposure to COVID-19; for COVID-19 testing prior to arrival to the cath lab; for clear communication between the referring physician and the interventionalist; but there was initial uncertainty among physicians regarding the optimal management of ST elevation myocardial infarction (STEMI; percutaneous coronary intervention versus thrombolytics). Patients with stable angina and hemodynamically stable acute coronary syndromes were deemed suitable for initial medical management, except when they had large ischemic burden. Most transcatheter aortic valve implantations (TAVI) were felt appropriate for postponement except in symptomatic patients with aortic valve area <0.5 cm(2) or recent hospitalization for heart failure (HF). Most percutaneous mitral valve repair (pMVR) procedures were felt appropriate for postponement except in patients with HF. All left atrial appendage closure (LAAC) and patent foramen ovale (PFO)/atrial septal defect (ASD) closure procedures were felt appropriate for postponement. CONCLUSION: Our survey of an experienced team of clinicians yielded concise guidelines to direct the management of CAD and structural heart disease patients during the initial phases of the COVID-19 pandemic.

In light of the recent COVID-19 pandemic, professional societies have released broad guidelines for the management of cath lab patients during the pandemic 1, 2 . Initial guidelines focused largely on coronary interventions and do not address the care of patients who require structural heart interventions (eg. TAVI, pMVR, LAAC, PFO/ASD closure). Further, it is unclear whether physicians uniformly agree with professional society guidelines and significant questions remain unanswered. For example, which elective coronary and structural heart interventions may be deferred till after the pandemic? How should we best manage STEMI: with PCI or thrombolytics?

When should personal protective equipment (PPE) be worn during a procedure? We surveyed interventional cardiologists, cardiac surgeons and imaging cardiologists in our multispecialty group to answer these questions. The purpose of this exercise was to create a framework that can serve as a ready reference for cath labs during the early phase of this pandemic, that encompasses not only coronary but also structural interventions, that prioritizes care to unstable patients without unnecessarily exposing stable patients to COVID-19 infection, that provides protection to hospital staff and cardiologists and respects the resource constraints our healthcare systems face.

Methods Across our multi-hospital healthcare delivery system, we surveyed 16 physicians [9 interventional cardiologists (IC, including 4 structural IC), an electrophysiologist experienced in left atrial appendage closure (LAAC), 2 imaging cardiologists and 4 cardiac surgeons] at 3 hospitals in Central and Northeastern Pennsylvania to delineate specific criteria to guide management of patients with coronary artery disease (CAD) and structural heart diseases [severe aortic stenosis (AS), mitral regurgitation (MR), atrial fibrillation with poor candidacy for oral anticoagulation (OAC), and patent foramen ovale (PFO)] and atrial septal defect (ASD)].

Using email communication, online questionnaire and conference calls, we conducted 2 separate surveys, one for CAD scenarios and 1 for structural heart interventions.

J o u r n a l P r e -p r o o f CAD: After an initial round of emails to explore common concerns, an electronic survey was conducted of 8 interventional cardiologists (IC) to delineate optimum treatment strategies for STEMI patients, focusing on the use of thrombolytics versus PCI, the need for COVID testing prior to cath lab arrival and use of PPE for cath lab staff and IC. Subsequently, we held a telephone conference call with all ICs in attendance to formalize system wide guidelines for each of the common CAD scenarios (STEMI, hemodynamically unstable acute coronary Discussion Although there was significant initial disagreement among IC about the management of STEMI and use of PPE (figures 1A-1E), we were able to achieve consensus and derive a concise framework for the care of patients with CAD (table 1) and those requiring structural heart interventions (table 2) during the early phases of the COVID-19 pandemic. The guiding principle of our framework is to provide judicious care to these vulnerable patients without unnecessarily exposing them or our teams to COVID-19. In the management of STEMI, the consensus was to continue to use primary PCI over thrombolytics. This is consistent with prior trials that have demonstrated greater efficacy of primary PCI over thrombolytics in the management of STEMI 3 .

The clinical benefit of primary PCI over thrombolytics is greater in anterior versus non-anterior myocardial infarction and in higher-risk patients 4, 5 . Hence, we specifically surveyed the 8 ICs on whether lytics should be considered in lower-risk subsets or inferior MI. Our surveyed group felt that we should continue to use primary PCI over thrombolytics for all STEMI cases, as we have traditionally done in the pre-COVID era. This is in contrast to the position paper from the

Members and Graduates 2 , that recommended consideration of lytic therapy for low-risk STEMI in the COVID era. Our specific recommendation to consider invasive management of all STEMI cases was guided by the concern that some patients presenting with STEMI may indeed have COVID myocarditis rather than coronary occlusion, and the use of lytic therapy in such cases J o u r n a l P r e -p r o o f may unnecessarily expose patients to increased risk of bleeding, especially intracranial hemorrhage.

The recently concluded ISCHEMIA trial of patients with stable CAD showed that initial invasive therapy provided greater improvement in angina-related health status but did not reduce the risk of ischemic cardiovascular events or death from any cause compared to initial conservative therapy 6, 7 . Consistent with prior observations that a high-risk non-invasive test is a marker of poor prognosis 8 , our surveyed physicians preferred an invasive approach over conservative management in stable CAD patients with a large ischemic burden.

Subsequent to the conduct of our surveys, professional societies in the US also released guidelines for structural heart interventions 9 , which closely resembled those our structural team agreed upon. Many ongoing developments in the management of COVID-19 will influence how our approaches evolve. These include the availability of point-of-care testing for COVID-19, the prevalence of myocarditis in patients presenting with ST elevations on the initial EKG 10 , the success of definitive antiviral treatment strategies, and the availability of preventive strategies, including vaccines. While institutional priorities, medicolegal concerns, financial concerns related to diminished productivity, and constraints on local resources will vary across systems, our study establishes that system wide policies can be implemented at short notice with appropriate involvement of clinicians and administrative leadership.

A major limitation of our paper is that our recommendations are based on the collective opinions of an experienced team of interventionalists working in an integrated health care system. There are currently no data to support the recommendations made by our team or professional societies. Further, as COVID cases decline, recommendations for the care of patients with coronary and structural heart disease will evolve in ways that are hard to predict. 

from the American College of Cardiology's (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI), Catheterization Laboratory Considerations During the

COVID-19) Pandemic: From ACC's Interventional Council and SCAI

Considerations for Cardiac Catheterization Laboratory Procedures During the COVID-19

Pandemic Perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) Members and Graduates. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials

Factors influencing myocardial salvage with primary angioplasty

Thrombolysis followed by coronary angiography versus primary percutaneous coronary intervention in non-anterior STelevation myocardial infarction

ISCHEMIA Research Group. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease

Initial Invasive or Conservative Strategy for Stable Coronary Disease

Appropriate Use Criteria for CoronaryRevascularization in Patients With Stable Ischemic Heart Disease : A Report of the

American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons

Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China